Skip to content

Multicenter, randomization, clinical control group, evaluator blinding, exploratory clinical trial to evaluate clinical effectiveness and safety of suicide prevention effect for patients with major depressive disorder using emotional disorder treatment software (CHEEU Forest) using virtual reality technology test

Multicenter, randomization, clinical control group, evaluator blinding, exploratory clinical trial to evaluate clinical effectiveness and safety of suicide prevention effect for patients with major depressive disorder using emotional disorder treatment software (CHEEU Forest) using virtual reality technology test

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CRIS
Registry ID
KCT0009382
Enrollment
70
Registered
2024-04-30
Start date
2022-06-13
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : 1. subjects: patients with depression and suicide risk findings 2. Main intervention: - Virtual reality based software treatment group: once a week for a total of 6 sessions for 6 wee

Sponsors

Yonsei University Health System, Gangnam Severance Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Selection criteria for clinical trial group and clinical control group 1) Men and women over 19 years old and under 50 years old who agreed to participate in the study. 2) Those with a mental health screening assessment (PHQ-9) score of 7 or higher -A study on Korean scale standardization for clinical trial groups (Ahn Je-yong et al., 2013) suggested 9 points as the cut-off point, but considering that it is a screening test for the general population, the cut-off point was set at 7 points to increase sensitivity and lower specificity. 3) Applicable to major depressive disorder (F.32) in the Korean version of the Clinical Neuropsychiatric Interview (MINI; Yoo Sang-woo et al., 2006) and without psychotic symptoms 4) Those with a suicidality score of 2 or more and 9 or less on the Korean version of the MINI International Neuropsychiatric Interview - Those who scored 9 points or less on the suicidality evaluation scale of the Korean version of the Clinician Evaluation Interview Module C and who did not attempt suicide within the past month (those who answered ‘No’ to item C5) were selected as subjects. (Subjects who answered “yes” to item C5 were excluded from the study group and a suicide crisis intervention program was implemented.) 2. Healthy control group 1) Men and women over 19 years old and under 50 years old who agreed to participate in the study. 2) Below the cutoff score for depression screening (5 points or less) in the Mental Health Screening Assessment (PHQ-9) 3) Subjects who do not meet a significant psychiatric diagnosis in each module of the Korean version of the MINI international Neuropsychiatric Interview 4) Subjects with a suicidality score of 1 or less on the Korean version of the MINI International Neuropsychiatric Interview

Exclusion criteria

Exclusion criteria: 1) People who have difficulty using virtual reality VR equipment 2) Those with a suicidality score of 10 or more on the Korean version of the MINI International Neuropsychiatric Interview (Excluding research participation, crisis intervention, psychiatric intensive treatment including drug treatment, implemented immediately) 3) Those who meet the level of intellectual disability in a shortened intelligence test (arithmetic & common sense) (less than 70 points in a shortened intelligence test) 4) During the trial period, those whose suicide risk increases or their depressive symptoms worsen to the extent that it is difficult to participate in the clinical trial according to self-report or clinician evaluation will be dropped out and receive intensive psychiatric treatment, including crisis intervention and drug treatment. 5) Those who are classified as psychotic disorder or addictive disorder according to clinical evaluation interview 6) Those with a history of taking antidepressants, anti-anxiety drugs, or antipsychotic drugs in the past 6 months 7) Pregnant or lactating women 8) Foreigners and illiterate people who cannot read the consent form 9) Other people who are unable to participate in this clinical trial at the discretion of the investigator

Design outcomes

Primary

MeasureTime frame
Descriptive statistics for the change in K-QIDS-C (Depression Rating Scale-Clinician Rating) scores

Secondary

MeasureTime frame
Descriptive statistics for the change in MINI-C suicidality scores ;Descriptive statistics for the change in depression(PHQ-9, HAM-D), anxiety(GAD-7), and stress (PSS) scores ;Comparison of symptom level assessment (CGI-S) levels among the Clinical Global Impression scale;Comparison before/after therapeutic intervention (CGI-I) of the Clinical Global Impression scale;Stability evaluation variable - SSQ score comparison;Stability evaluation variable - Check whether the FIBSER score is 3 or more

Countries

Korea, Republic of

Contacts

Public ContactKim Hyeongtaek

Yonsei University Health System, Gangnam Severance Hospital

gnsv.kht@yuhs.ac+82-2-2019-3343

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026